California Healthline February 22, 2023
Sarah Jane Tribble

A prescription drug that helps Lore Wilkinson walk and talk despite a rare muscle disease cost her so little for more than a decade that she didn’t even use her insurance to pay for it. But now, her Medicare insurance is shelling out about $40,000 for a one-month supply of the drug, and she fears she’ll be slammed with a $9,000 copayment.

“Who can afford that?” said the 91-year-old, who lives in Rochester, Minnesota. (Her first name is pronounced LOR-ee.)

Wilkinson, like millions of other people with rare diseases nationwide, is caught up in an ongoing legal and political debate about how the U.S. supports pharmaceutical companies and their research. The FDA made its latest move in the tug of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Patient / Consumer, Provider
The risk of a bird flu pandemic is rising
Epidemics then and now: Managing loneliness, burnout, and social media toxicity
Human-AI Collaboration: Keep The Machines On A Short Leash
Patient Portals 4.0: Future of Patient Engagement
AI tool could predict type 2 diabetes 10 years in advance

Share This Article